Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 30, 2010, Pages 13252-13257

  Spangler, Jamie B ^a   Neil, Jason R ^a   Abramovitch, Sivan ^b   Yarden, Yosef ^b   White, Forest M ^a   Lauffenburger, Douglas A ^a   Wittrup, K Dane ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

^b WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

ErbB; Monoclonal antibody; Trafficking; Tyrosine kinase

Indexed keywords

ANTIBODY; CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; LIGAND; MONOCLONAL ANTIBODY; EPIDERMAL GROWTH FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CELL LINE; CELL PROLIFERATION; CLINICAL ASSESSMENT; CLINICAL FEATURE; CONTRAST; DOWN REGULATION; ENDOSOME; HUMAN; MIGRATION; NEOPLASM; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR DOWN REGULATION; RECYCLING; REGULATORY MECHANISM; SURFACE PROPERTY; TUMOR GROWTH; ALGORITHM; ANIMAL; CELL MOTION; CHO CELL LINE; CRICETULUS; DRUG EFFECTS; ENDOCYTOSIS; FLOW CYTOMETRY; HAMSTER; HELA CELL LINE; HT 29 CELL LINE; IMMUNOLOGY; KINETICS; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ALGORITHMS; ANIMALS; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CHO CELLS; CRICETINAE; CRICETULUS; DOWN-REGULATION; ENDOCYTOSIS; ENDOSOMES; EPIDERMAL GROWTH FACTOR; FLOW CYTOMETRY; HELA CELLS; HT29 CELLS; HUMANS; KINETICS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 77955796080     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0913476107     Document Type: Article

References (44)

1. Ferguson KM, et al. (2003) EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell 11:507-517.
2. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137.
3. Abella JV, Park M (2009) Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases. Am J Physiol Endoc M 296:E973-984.
4. Wiley HS (2003) Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 284:78-88.
5. Mendelsohn J (2001) The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8:3-9. (Pubitemid 32520250)
6. Carter P (2001) Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1:118-129.
7. Grunwald V, Hidalgo M (2003) Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 95:851-867. (Pubitemid 36833877)
8. Li S, et al. (2005) Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 7:301-311. (Pubitemid 40544648)
9. Cohenuram M, Saif MW (2007) Panitumumab the first fully human monoclonal antibody: From the bench to the clinic. Anticancer Drugs 18:7-15. (Pubitemid 44949790)
10. Cunningham D, et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345.
11. Van Cutsem E, et al. (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patientswith chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664.
12. Martinelli E, De Palma R, Orditura M, De Vita F, Ciardiello F (2009) Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. Clin Exp Immunol 158:1-9.
13. Friedman LM, et al. (2005) Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: Implications for cancer immunotherapy. Proc Natl Acad Sci USA 102:1915-1920.
14. Perera RM, et al. (2005) Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 11:6390-6399.
15. Pedersen MW, et al. (2010) Sym004: A novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 70:588-597.
16. Kamat V, et al. (2008) Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther 7:726-733.
17. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M (2009) Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis. Proc Natl Acad Sci USA 106:3294-3299.
18. Zhu JX, et al. (2005) Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis. J Biol Chem 280:32468-32479.
19. Wiley HS (1988) Anomalous binding of epidermal growth factor to A431 cells is due to the effect of high receptor densities and a saturable endocytic system. J Cell Biol 107:801-810.
20. Chao G, Cochran JR, Wittrup KD (2004) Fine epitope mapping of anti-epidermal growth factor receptor antibodies through random mutagenesis and yeast surface display. J Mol Biol 342:539-550.
21. Ogiso H, et al. (2002) Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110:775-787.
22. Kominek LA (1975) Cycloheximide production by Streptomyces griseus: Alleviation of end-product inhibition by dialysis-extraction fermentation. Antimicrob Agents Chemother 7:861-863.
23. Basu SK, Goldstein JL, Anderson RG, Brown MS (1981) Monensin interrupts the recycling of low density lipoprotein receptors in human fibroblasts. Cell 24:493-502.
24. Wang Y, Pennock S, Chen X, Wang Z (2002) Endosomal signaling of epidermal growth factor receptor stimulates signal transduction pathways leading to cell survival. Mol Cell Biol 22:7279-7290.
25. Downward J, Waterfield MD, Parker PJ (1985) Autophosphorylation and protein kinase C phosphorylation of the epidermal growth factor receptor. Effect on tyrosine kinase activity and ligand binding affinity. J Biol Chem 260:14538-14546.
26. Margolis BL, et al. (1989) All autophosphorylation sites of epidermal growth factor (EGF) receptor and HER2/neu are located in their carboxyl-terminal tails. Identification of a novel site in EGF receptor. J Biol Chem 264:10667-10671.
27. Sato K, Sato A, Aoto M, Fukami Y (1995) c-Src phosphorylates epidermal growth factor receptor on tyrosine 845. Biochem Biophys Res Commun 215:1078-1087.
28. Countaway JL, Nairn AC, Davis RJ (1992) Mechanism of desensitization of the epidermal growth factor receptor protein-tyrosine kinase. J Biol Chem 267:1129-1140.
29. Takishima K, Griswold-Prenner I, Ingebritsen T, Rosner MR (1991) Epidermal growth factor (EGF) receptor T669 peptide kinase from 3T3-L1 cells is an EGF-stimulated "MAP" kinase. Proc Natl Acad Sci USA 88:2520-2524.
30. Hunter T, Ling N, Cooper JA (1984) Protein kinase C phosphorylation of the EGF receptor at a threonine residue close to the cytoplasmic face of the plasma membrane. Nature 311:480-483.
31. Joslin EJ, Opresko LK, Wells A, Wiley HS, Lauffenburger DA (2007) EGF-receptor-mediated mammary epithelial cell migration is driven by sustained ERK signaling from autocrine stimulation. J Cell Sci 120:3688-3699.
32. French AR, Lauffenburger DA (1996) Intracellular receptor/ligand sorting based on endosomal retention components. Biotechnol Bioeng 51:281-297.
33. French AR, Lauffenburger DA (1997) Controlling receptor/ligand trafficking: Effects of cellular and molecular properties on endosomal sorting. Ann Biomed Eng 25:690-707.
34. Marmor MD, Yarden Y (2004) Role of protein ubiquitylation in regulating endocytosis of receptor tyrosine kinases. Oncogene 23:2057-2070.
35. Jorissen RN, et al. (2003) Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 284:31-53.
36. Harms BD, Bassi GM, Horwitz AR, Lauffenburger DA (2005) Directional persistence of EGF-induced cell migration is associated with stabilization of lamellipodial protrusions. Biophys J 88:1479-1488.
37. Huang PH, et al. (2007) Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc Natl Acad Sci USA 104:12867-12872.
38. Austin CD, et al. (2004) Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 15:5268-5282.
39. Jaramillo ML, et al. (2006) Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting. Exp Cell Res 312:2778-2790.
40. Zhang Y, et al. (2005) Time-resolved mass spectrometry of tyrosine phosphorylation sites in the epidermal growth factor receptor signaling network reveals dynamic modules. Mol Cell Proteomics 4:1240-1250.
41. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS (1999) Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20:3551-3567.
42. Nichols AM, White FM (2009) Manual validation of peptide sequence and sites of tyrosine phosphorylation from MS/MS spectra. Methods Mol Biol 492:143-160.
43. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65:55-63.
44. Lauffenburger DA, et al. (1996) Engineering dynamics of growth factors and other therapeutic ligands. Biotechnol Bioeng 52:61-80.